JP2022554267A5 - - Google Patents

Info

Publication number
JP2022554267A5
JP2022554267A5 JP2022525193A JP2022525193A JP2022554267A5 JP 2022554267 A5 JP2022554267 A5 JP 2022554267A5 JP 2022525193 A JP2022525193 A JP 2022525193A JP 2022525193 A JP2022525193 A JP 2022525193A JP 2022554267 A5 JP2022554267 A5 JP 2022554267A5
Authority
JP
Japan
Prior art keywords
seq
composition according
sequence identity
polypeptide
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554267A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/058247 external-priority patent/WO2021087282A1/en
Publication of JP2022554267A publication Critical patent/JP2022554267A/ja
Publication of JP2022554267A5 publication Critical patent/JP2022554267A5/ja
Pending legal-status Critical Current

Links

JP2022525193A 2019-10-30 2020-10-30 組換えcdkl5タンパク質、遺伝子療法、及び製造方法 Pending JP2022554267A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962928140P 2019-10-30 2019-10-30
US201962928134P 2019-10-30 2019-10-30
US62/928,140 2019-10-30
US62/928,134 2019-10-30
US202063090520P 2020-10-12 2020-10-12
US63/090,520 2020-10-12
PCT/US2020/058247 WO2021087282A1 (en) 2019-10-30 2020-10-30 Recombinant cdkl5 proteins, gene therapy and production methods

Publications (2)

Publication Number Publication Date
JP2022554267A JP2022554267A (ja) 2022-12-28
JP2022554267A5 true JP2022554267A5 (cg-RX-API-DMAC7.html) 2023-11-06

Family

ID=75716480

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525193A Pending JP2022554267A (ja) 2019-10-30 2020-10-30 組換えcdkl5タンパク質、遺伝子療法、及び製造方法

Country Status (9)

Country Link
US (1) US20230043046A1 (cg-RX-API-DMAC7.html)
EP (1) EP4073231A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022554267A (cg-RX-API-DMAC7.html)
KR (1) KR20220106981A (cg-RX-API-DMAC7.html)
CN (1) CN114901802A (cg-RX-API-DMAC7.html)
AU (1) AU2020372988A1 (cg-RX-API-DMAC7.html)
CA (1) CA3156506A1 (cg-RX-API-DMAC7.html)
TW (1) TW202136514A (cg-RX-API-DMAC7.html)
WO (1) WO2021087282A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021218703A1 (en) 2020-02-14 2022-07-28 Ultragenyx Pharmaceutical Inc. Gene therapy for treating CDKL5 deficiency disorder
WO2022119890A1 (en) 2020-12-01 2022-06-09 The Trustees Of The University Of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
KR20240100490A (ko) * 2021-10-18 2024-07-01 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Cdkl5 결핍 장애(cdd)의 치료에 유용한 조성물
WO2023077143A1 (en) * 2021-11-01 2023-05-04 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of cdkl5 deficiency disorder (cdd)
AU2023288029A1 (en) * 2022-06-21 2025-02-13 Skyline Therapeutics Limited Recombinant aav for the gene therapy of sma disease
CN116377050A (zh) * 2022-12-16 2023-07-04 湖南家辉生物技术有限公司 一种发育性癫痫性脑病2型致病基因cdkl5突变位点的应用及其检测试剂和应用
WO2025050032A1 (en) * 2023-08-31 2025-03-06 Ultragenyx Pharmaceutical Inc. Methods of producing cdkl5 proteins and uses of the same
CN118638212B (zh) * 2024-06-18 2025-07-04 河北绶肽生物科技有限公司 一种烟草表达的重组人源ⅲ型胶原蛋白及其编码基因和制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2435562A1 (en) * 2009-05-26 2012-04-04 Biolex Therapeutics, Inc. Compositions and methods for production of aglycosylated plasminogen
HRP20181315T1 (hr) * 2010-11-22 2018-10-19 Amicus Therapeutics, Inc. Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
HUE055282T2 (hu) * 2014-02-28 2021-11-29 Univ Bologna Alma Mater Studiorum TATK-CDKL5 fúziós fehérjék, készítmények, formulák és azok alkalmazása
EP3632923A1 (en) * 2015-01-16 2020-04-08 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
WO2017180587A2 (en) * 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US20210268072A1 (en) * 2016-06-28 2021-09-02 Alma Mater Studiorum - Universitá Di Bologna TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
EP3562494A4 (en) * 2016-12-30 2020-08-19 The Trustees Of The University Of Pennsylvania GENE THERAPY FOR THE TREATMENT OF PHENYLKETONURIS
US11938197B2 (en) * 2017-01-10 2024-03-26 The Sydney Children's Hospitals Network (Randwick And Westmead (Incorporating The Royal Alexandra Hospital For Children) Polynucleotides and vectors for the expression of transgenes
EP4585229A3 (en) * 2017-11-08 2026-01-14 Novartis AG Means and method for preparing viral vectors and uses of same
CN111936624A (zh) * 2017-11-30 2020-11-13 阿米库斯治疗学公司 Cdkl5表达变体和cdkl5融合蛋白
WO2020191241A1 (en) * 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
IT201900008877A1 (it) * 2019-06-13 2020-12-13 Univ Bologna Alma Mater Studiorum Nuovi costrutti per terapia genica

Similar Documents

Publication Publication Date Title
JP2020203894A5 (cg-RX-API-DMAC7.html)
JP2023070682A5 (cg-RX-API-DMAC7.html)
JP7350485B2 (ja) ウイルスベクター効率を改善するための組成物及び方法
Wang et al. Comparison of adenoviral and adeno-associated viral vectors for pancreatic gene delivery in vivo
JP2019505588A5 (ja) 遺伝子治療ベクターおよび医薬組成物
US20180073018A1 (en) Compositions and methods for specific reactivation of hiv latent reservoir
JP2025166834A5 (cg-RX-API-DMAC7.html)
JP2021512126A5 (cg-RX-API-DMAC7.html)
Shi et al. Modulation of the specificity and activity of a cellular promoter in an adenoviral vector
JP2015523379A5 (cg-RX-API-DMAC7.html)
JP2019519219A5 (cg-RX-API-DMAC7.html)
JP2018502583A5 (cg-RX-API-DMAC7.html)
JP2022513308A5 (cg-RX-API-DMAC7.html)
JP2016500519A5 (cg-RX-API-DMAC7.html)
JP2018537089A5 (cg-RX-API-DMAC7.html)
JP2021536250A5 (cg-RX-API-DMAC7.html)
CN116440292A (zh) Danon病和其它自噬障碍的治疗方法
JP2010504909A5 (cg-RX-API-DMAC7.html)
JP2020533969A5 (cg-RX-API-DMAC7.html)
IL262459B2 (en) Compositions and methods for increased gene expression of pklr for the treatment of pyruvate kinase deficiency
JP2019530462A5 (cg-RX-API-DMAC7.html)
JP2022530095A5 (cg-RX-API-DMAC7.html)
JP2020172505A5 (cg-RX-API-DMAC7.html)
JP2017521074A5 (cg-RX-API-DMAC7.html)
JP2020503265A5 (cg-RX-API-DMAC7.html)